Lv5
1308 积分 2024-07-10 加入
From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma
9小时前
求助中
Osteoclasts in osteoradionecrosis: Pathogenic mechanisms and emerging therapies
15小时前
待确认
Prevention and treatment of post-irradiation fractures and other complications
15小时前
已关闭
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
3天前
已完结
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
3天前
已完结
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
4天前
已完结
Five‐Year Follow‐Up: Tandem CD19 / CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non‐Hodgkin Lymphoma
6天前
已完结
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
7天前
已完结
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis
7天前
已完结
A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma
7天前
已完结
皖公网安备34019202002308
